4
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Ascorbic acid for the treatment of methemoglobinemia: the experience of a large tertiary care pediatric hospital.

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          The purpose of reporting this series of patients is to illustrate the role of ascorbic acid in the treatment of severe acquired methemoglobinemia (metHb), especially when methylene blue is not available. Medical records of affected patients were reviewed to collect history of exposures, food ingestion, physical examination, pulse oximetry, blood gas, and co-oximetry results, and outcomes. Five cases of acquired metHb are presented here, all of whom received treatment with ascorbic acid and fully recovered after 24 hours of treatment. Our series emphasizes that ascorbic acid is an effective alternative in the management of acquired metHb if methylene blue is unavailable and suggests that ascorbic acid infusion may be indicated in patients with glucose-6-phosphatase dehydrogenase deficiency.

          Related collections

          Author and article information

          Journal
          Am J Ther
          American journal of therapeutics
          Ovid Technologies (Wolters Kluwer Health)
          1536-3686
          1075-2765
          June 11 2014
          : 21
          : 4
          Affiliations
          [1 ] 1Division of Pediatric Emergency Medicine, Hospital de Pediatría Prof. Dr. Juan P. Garrahan, Buenos Aires, Argentina; 2Division of Pediatric Emergency Medicine, Department of Pediatrics, The Hospital for Sick Children, University of Toronto, Ontario, Canada; 3Division of Clinical Pharmacology and Toxicology, The Hospital for Sick Children, University of Toronto, Ontario, Canada; 4Division of Pediatric Emergency Medicine, Department of Pediatrics, Dana-Dwek Children Hospital, University of Tel Aviv, Tel Aviv, Israel; and 5Division of Clinical Pharmacology and Toxicology, Ichilov Hospital, University of Tel Aviv, Tel Aviv, Israel.
          Article
          10.1097/MJT.0000000000000028
          24914501
          d9632f29-c227-4fcc-93ff-81c8b7985320

          Comments

          Comment on this article